Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

4.3%

1 terminated/withdrawn out of 23 trials

Success Rate

94.1%

+7.6% vs industry average

Late-Stage Pipeline

39%

9 trials in Phase 3/4

Results Transparency

13%

2 of 16 completed trials have results

Key Signals

3 recruiting2 with results

Enrollment Performance

Analytics

Phase 2

8(36.4%)

Phase 3

6(27.3%)

Phase 1

5(22.7%)

Phase 4

3(13.6%)

22Total

Phase 2(8)

Phase 3(6)

Phase 1(5)

Phase 4(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (23)

Showing 20 of 23 trials

NCT06629389Phase 2Recruiting

Clinical Trial with Cannabidiol (Kanbis®) for Parkinson Disease Symptoms

Role: lead

NCT05668650Phase 3Recruiting

Double-blind Study to Evaluate the PK, Efficacy, Safety and Immunogenicity of MB12 Versus Keytruda® in Stage IV NSCLC

Role: lead

NCT04897516Phase 3Recruiting

Shorter Benznidazole Regimens Compared to the Standard Regimen for Chagas Disease

Role: lead

NCT02998983Phase 2Completed

Racotumomab in Patients With High-risk Neuroblastoma

Role: lead

NCT04954235Completed

Effectiveness and Safety Study of Specific Hyperimmune Equine Serum for the Treatment of Severe Hospitalized SARS-CoV-2 in Adults: Retrospective Cohort Study

Role: collaborator

NCT04560881Phase 3Completed

Clinical Trial to Evaluate the Efficacy, Immunogenicity and Safety of the Inactivated SARS-CoV-2 Vaccine (COVID-19)

Role: lead

NCT04355936Phase 4Completed

Telmisartan for Treatment of COVID-19 Patients

Role: lead

NCT03668054Phase 3Completed

Safety and Clinical Effectiveness of Intravitreal Bevacizumab (Lumiere®) in Patients With Wet Age-related Macular Degeneration (Wet AMD)

Role: lead

NCT04381884Phase 2Completed

Ivermectin Effect on SARS-CoV-2 Replication in Patients With COVID-19

Role: lead

NCT02268045Phase 3Completed

Study of RTXM83 Plus CHOP Chemotherapy Versus a Rituximab Plus CHOP Therapy in Patients With Non Hodgkin's Lymphoma

Role: collaborator

NCT02069704Phase 1Completed

Bioequivalence Study Bevacizumab Biosimilar (BEVZ92) Versus Bevacizumab (AVASTIN®) in First-line Treatment mCRC Patients

Role: collaborator

NCT03317236Phase 4Completed

Bioequivalence Study of Two Extended Release Formulations Containing 50 mg of Quetiapine.

Role: lead

NCT03309566Phase 4Completed

Bioequivalence Study of Two Formulatiosns With the Asscociaton of Efavirenz, Emtricitabine and Tenofovir

Role: lead

NCT01623206Phase 2Completed

Desmopressin (DDAVP) in Patients With Colorectal Cancer and Rectal Bleeding

Role: lead

NCT01639625Phase 2Completed

Concurrent Treatment of Squamous Cell Carcinoma or Adenocarcinoma of the Cervix With CIGB-300 for Local Application

Role: lead

NCT01460472Phase 3Unknown

Immunotherapy With Racotumomab in Advanced Lung Cancer

Role: collaborator

NCT02583464Phase 1Completed

Bioequivalence Study of Two Formulations With the Association of Tenofovir 300 mg and Emtricitabine 200 mg.

Role: lead

NCT01606072Phase 2Completed

Perioperative Use of Desmopressin (DDAVP) in Breast Cancer

Role: lead

NCT01598454Phase 1Completed

Use of Racotumomab in Patients With Pediatric Tumors Expressing N-glycolylated Gangliosides

Role: lead

NCT01639638Phase 2Terminated

Recurrent and Nonrecurrent Condyloma Treatment

Role: lead